Synthesis and docking of new Schiff-bases bearing urea as promising dual α-amylase and α-glucosidase inhibitors
- PMID: 40577028
- PMCID: PMC12296107
- DOI: 10.1080/17568919.2025.2520155
Synthesis and docking of new Schiff-bases bearing urea as promising dual α-amylase and α-glucosidase inhibitors
Abstract
Aims: To synthesise and evaluate new amino biaryl-urea (3a-h) and Schiff base urea derivatives (5a-h) for their in vitro antidiabetic activity against α-glucosidase and α-amylase.
Materials and methods: A series of Schiff base urea derivatives were synthesised through a two-step procedure: condensation of 4-chloro-o-phenylenediamine with isocyanates to form amino biaryl-urea derivatives (3a-h), followed by reaction with 2-hydroxy-naphthaldehyde. The new compounds were characterized using 1H and 13C NMR, as well as high-resolution mass spectrometry. Inhibition assays were conducted to determine IC50 values of all compounds against α-amylase and α-glucosidase.
Results: Derivatives 3g and 3h exhibited the strongest enzyme inhibition, with IC50 values of 10.06 ± 0.32 µM (α-amylase) and 21.23 ± 1.27 µM (α-glucosidase), respectively. These compounds displayed activity comparable to the standard drug acarbose. Docking studies revealed that 3g interacts with key residues TRP59 and GLN63 of α-amylase, supporting the experimental findings.
Conclusions: The di-fluoro and di-chloro substituents in compounds 3g and 3 h enhance their antidiabetic activity, suggesting their potential as effective inhibitors of carbohydrate-metabolizing enzymes. Further studies are warranted to explore the therapeutic applications of these derivatives.
Keywords: Schiff base; Synthesis; molecular docking; molecular dynamics; α-amylase; α-glucosidase.
Conflict of interest statement
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Similar articles
-
One-Pot Synthesis of Novel Pyrimidine Derivatives with Potential Antidiabetic Activity Through Dual α-Glucosidase and α-Amylase Inhibitors.Molecules. 2025 Jul 4;30(13):2857. doi: 10.3390/molecules30132857. Molecules. 2025. PMID: 40649371 Free PMC article.
-
Design, synthesis, characterization, in silico, in vitro and in vivo antidiabetic studies of novel benzothiophene derivatives.J Comput Aided Mol Des. 2025 Aug 6;39(1):59. doi: 10.1007/s10822-025-00638-9. J Comput Aided Mol Des. 2025. PMID: 40767979
-
Development of 1,2,3-Triazoles as Dual Enzyme Inhibitors Targeting α-Amylase and α-Glucosidase for Type 2 Diabetes Intervention.Arch Pharm (Weinheim). 2025 Sep;358(9):e70088. doi: 10.1002/ardp.70088. Arch Pharm (Weinheim). 2025. PMID: 40899410
-
Dual α-amylase and α-glucosidase inhibitors: recent progress from natural and synthetic resources.Bioorg Chem. 2025 Aug;163:108762. doi: 10.1016/j.bioorg.2025.108762. Epub 2025 Jul 18. Bioorg Chem. 2025. PMID: 40706540 Review.
-
Recent Developments in 1,2,3-Triazole Based α-Glucosidase Inhibitors: Design Strategies, Structure-Activity Relationship and Mechanistic Insights.Chem Biodivers. 2024 Sep;21(9):e202401109. doi: 10.1002/cbdv.202401109. Epub 2024 Aug 22. Chem Biodivers. 2024. PMID: 38951966 Review.
References
-
- Magliano DJ, Boyko EJ.. IDF diabetes atlas. In: 10th edition scientific committee. Brussels: International Diabetes Federation; 2022.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical